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Chemotherapy uses drugs to kill cancer cells, either by preventing them from multiplying or by causing 
the cells to self-destruct. However, in most cases, high systemic toxicity and drug resistance limit the 
successful outcomes of treatment regimes. Prevention of cancer through dietary intervention recently 
has received an increasing interest and dietary polyphenols have become not only important potential 
chemopreventive, but also therapeutic, natural agents. Combination of effective chemopreventive agent 
(such as ginger) with chemotherapeutic agents may enhance efficacy while reducing toxicity to normal 
tissues, resulting in better survival. In this study, we observed that treatment of human cervical 
carcinoma cell line, HeLa with ethanolic ginger extract in combination with gemcitabine resulted in 
significant dose-dependent decrease in cell viability. It is noteworthy that use of ginger extract 
increased the efficacy of gemcitabine and importantly, it was found to be minimally toxic to normal 
cells. Together, these results suggest a novel mechanism may be involved in the synergistic effect of 
this combination. Thus, this combination may be an effective modality management in the treatment of 
cervical cancer. 
 





Cancer treatments involve the various modalities inclu-
ding surgery, radiation therapy, immunotherapy, hormone 
therapy or chemotherapy. The choice of treatment 
depends on the location and stage of the cancer (Aapro 
et al., 1998). Chemotherapeutic medicines usually target 
cells that quickly divide. However, normal cells - including 
those found in the blood, hair and the lining of the 
gastrointestinal tract - also divide very quickly. Hence, 
chemotherapy can also damage or kill these healthy cells 
leading to side effects such as nausea and vomiting 
(64%), transient elevation of serum transaminases (68%, 
2% severe), proteinuria (36%), fever (37%), hematuria 
(31%), dermatologic rash (25%), edema (20%), Flu-like 
syndrome (19%), alopecia (14%), diarrhea (12%), con-
stipation(8%), thrombocytopenia (5%), etc (Abratt et al., 
1994; Aapro et al., 1998; Canavan and Doshi, 2000).  
Emerging evidence suggests that cancer preventative 
agents might be combined with chemotherapy or radio-
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binational therapy may act in an additive or synergistic 
fashion to maximally activate molecular pathways that 
inhibit carcinogenesis, thereby maximizing cancer preven-
tion while minimizing side effects (Hida et al., 2000, 2002; 
Piazza et al., 2009). Recent efforts to potentiate the 
effectiveness and minimizing cytotoxicity of chemo-
therapy have focused on using traditional chemopreven-
tive agents (that is, genistein, 3, 3’ -diindolylmethane, 
indole- 3 -carbinol (I3C), curcumin, (-)-epigallocatechin- 3 
-gallate (EGCG), resveratrol, etc.) These have been 
recognized as cancer chemopreventive agents because 
of their anti carcinogenic activity as biological response 
modifiers, revising the activity of key cell proliferation, 
angiogenic and survival pathways (Brock et al., 1988; 
Dragsted, 1998; Lippman et al., 1998; Wargovich, 1999; 
Kelloff, 2000; Li et al., 2005; Hwang et al., 2005; Sarkar 
and Li, 2006; Aggarwal and Shishodia, 2006; Surh and 
Na, 2008; Davidson and Touger, 2009).  
Ginger (Zingeiber officinale) is one of the most highly 
consumed dietary substances in the world (Surh, 2003). 
It has also been studied for its efficacy for acute chemo-
therapy-induced nausea and vomiting (CINV) (Zick et al., 
2009).   It  has  been  shown  to  contain  many  bioactive  




compounds which possess many attention-grabbing 
pharmacological and physiological activities (Surh et al., 
1998). Of these, [6] -gingerol (1 -[4' -hydroxy- 3 '- 
methoxy-phenyl]- 5 -hydroxy- 3 -decanone), the major 
pungent principle of ginger, has anti-oxidant, anti-
inflammation and anti-tumor promoting activities (Surh et 
al., 1998; Bode et al., 2001; Jagtap et al., 2009). The 
present study was designed to gain insights into the 
effects of combinational treatment of ginger extract and 
gemcitabine with emphasis on their ability to reduce toxic 
side effects on normal cells, while potentiating the 
efficacy of chemo-therapeutic treatment at lower doses.  
 
 




Human cervical carcinoma cell line, HeLa used in this study was 
kindly provided by Dr. K. Satyamoorthy (Manipal University, India). 
It was maintained in DMEM supplemented with 10% fetal bovine 
serum (FBS). The cell line was grown in 5% CO2 at 37°C, 100% 
humidity. Lymphocytes isolated from healthy non-smoking donors, 
were used as normal.  
 
 
Purification of lymphocytes 
 
Short term lymphocyte culture was performed. Fresh blood was 
collected in heparinised collection vials and used immediately for 
the experiments. Karyotyping was carried out to confirm the geno-
mic stability of the lymphocytes. Lymphocytes were isolated using 
HiSep Media (HiMedia, India) (as per the manufacturer’s instruc-
tions). Briefly, HiSep media was added to blood in the ratio 1:3 
(media: blood) and centrifuged at 160 g for 20 min. The 
lymphocytes were then separated into fresh tube and equal volume 
of PBS was added. This was again centrifuged at 140 g for 15 min 
for removal of HiSep Media. A second wash in PBS was given 
followed by centrifugation at 140 g for 15 min. The pellet was 




Preparation of gemcitabine solution 
 
A stock solution of 133 mM (40mg/ml) of Gemcitabine (Intas Bio-
pharmaceuticals, India) was prepared in 2% DMEM and further 




Preparation of crude ginger extract  
 
Powdered ginger was weighed (0.25 g) and extracted in 1000 l of 
50% ethanol in water for 7 days at 4°C (Rhode et al., 2007). The 
extract obtained was then centrifuged at 180 g for 20 min. Super-
natant was collected and filtered using 0.2 m filter (Whatmann Inc. 
UK). Dilutions of crude extract from 0.005 - 1.1 mg/ml were pre-
pared in 2% DMEM.  
 
 
Cell viability assay to determine LD50 of gemcitabine and 
ginger extract  
 
HeLa cells were harvested and counted using hemocytometer 





(in triplicates) in 96 well plates and incubated for 24 h in complete 
medium. Then the cells were treated with different concentrations of 
ginger extract ranging from 0.005-1.1 mg/ml. Cells with and without 
treatment were then incubated with MTT (Sigma-Aldrich) at final 
concentration of 0.5 mg/ml at 37°C for 2-4 h. Viable cells have 
intact mitochondria and dehydrogenases present therein convert 
the tetrazolium salt to insoluble formazan violet crystals (Cartwright 
et al., 1997; Dash et al., 2003). The formazan crystals were 
dissolved in 100l of DMSO (Sigma, Aldrich). The absorbance was 
read at 570 nm in an Absorbance Microplate Reader (BioTek, 
U.S.A). Similarly, lymphocytes were also treated with ginger extract 
(0.001-1 mg/ml) for 24 h. MTT was performed ad described above. 
The experiments were repeated at least three times. 
 
Growth Inhibition is expressed as:  
 
Cell Viability (%) = (Average OD of individual test group / Average 
OD of controls) x 100 
 
 
Determination of cell viability after combinational treatment 
 
Cells were harvested, counted using hemocytometer (Marienfeild, 
Germany) and plated as described above. After 24 h incubation, 
cells were treated with gemcitabine (5 mM) alone, ginger extract 
(0.8 and 0.85 mg/ml) alone and their combinations for 24 h. Cells 
with and without treatment were incubated with MTT at final con-
centration of 0.5 mg/ml at 37°C for 2 - 4 h. The formazan crystals 
were dissolved in 100 l of DMSO. The absorbance was read at 
570 nm in an Absorbance Microplate Reader (BioTek, U.S.A). The 
experiment was reproduced at least three times. 
 
 
Morphological studies of cell line using normal inverted 
microscope 
 
Morphological changes in HeLa cells elicited by gemcitabine and 
ginger extract were documented using normal inverted microscope 
(Labomed, USA). The concentration of LD50 value of the respective 
drugs was used for the morphological studies. HeLa cells were 
treated with 35 mM gemcitabine or 0.96 mg/ml ginger extract for 24 
h. The untreated cells were used as negative control. Morphological 




RESULTS AND DISCUSSION 
 
Neoadjuvant chemotherapy represents a promising 
alternative to surgery or radiotherapy as initial treatment 
of locally advanced cervical cancer because of the possi-
bility, in responding patients, of obtaining wider un-
involved surgical margins. However, while many chemo-
therapeutic drugs can successfully kill fast-dividing 
cancer cells, the drugs also damage several types of 
rapidly proliferating normal cells such as the hema-
topoietic precursors, intestinal cells and hair follicle cells 
(Elst et al., 2007). This nonselective killing for rapidly 
proliferating normal cells often cause serious adverse 
effects in cancer patients, such as bone marrow suppres-
sion, anorexia (appetite loss), nausea, vomiting, diarrhea, 
stomatitis and alopecia (hair loss) and thus limits the 
doses of these drugs that can be tolerated (Elst et al., 
2007). 












Figure 2. Microscopic features of HeLa cells before treatment (A), after treatment with 35 mM gemcitabine (B), and 




Gemcitabine, a widely used chemotherapeutic drug is a 
ribonucleotide reductase inhibitor and exhibits cell phase 
specificity, primarily killing cells undergoing DNA syn-
thesis (S-phase) and also blocking the progression of 
cells through the G1/S phase boundary (Giovannetti et al., 
2004). HeLa cells and lymphocytes showed growth 
inhibition in a dose-dependent manner when treated with 
gemcitabine at concentrations ranging from 1-100 mM for 
24 h (Hussain et al., 2009). As described previously, the 
LD50 value of gemcitabine was found to be 35 mM on 
HeLa cells and 50 mM on lymphocytes (Hussain et al., 
2009). The morphological features observed using the 
normal inverted microscope showed characteristic 
rounding of dying cells on treatment with 35 mM 
gemcitabine for 24 h compared to untreated control 
(Figures 2a, b). Similar dose dependent decrease in cell 
viability was observed when lymphocytes were treated 
with gemcitabine with LD50 at 50 mM (Figure 3). Thus 
gemcitabine was slightly more toxic to cancer cells than 
normal lymphocytes due to the rapid proliferation of HeLa 
cells, a characteristic of cancer cells; hence the latter 
remains target for gemcitabine drug (Giovannetti et al., 
2004). Weiss and coworkers have also shown that tumor 
cells are more sensitive to cell death by chemothe-
rapeutic drugs than normal cells (Weiss et al., 1988). 
Recently, much focus has been attributed to dietary 
compounds such as curcumin, resveratrol, genistein, 
ginger, garlic, chilies and green tea as cancer chemo-
preventive agents because of their anti carcinogenic 
activity with minimal toxicity on normal cells (Adhami and 
Mukhtar, 2007; Thasni et al., 2008; Bishayee, 2009; 
Jagtap et al., 2009; Kundu et al., 2009; Nian et al., 2009).  












Figure 4. Dose dependent curve of ethanolic ginger extract (0.005 - 1.1 mg/ml) on HeLa cells treated for 24 




Moreover, these compounds also exert the antitumor 
activities through regulation of different cell signaling 
pathways. HeLa cells treated with ginger extract (0.005 - 
1.1 mg/ml) for 24 h (Figure 4) showed growth inhibition in 
a dose-dependent manner. The LD50 value of ginger 
extract on HeLa cells was found to be 0.96 mg/ml. The 
morphological changes observed using the normal 
inverted microscope show characteristic rounding off of 
dying cells on treatment with lethal dose (0.96 mg/ml) of 
ginger extract for 24 h in comparison with untreated 
control (Figures 1a, c).  
It is well established that chemopreventive  drugs  have  






Figure 5. Lymphocytes treated with different concentrations (0.001 - 1.0 mg/ml) of ethanolic ginger 




differential effect on cancer cells and normal cells in vivo 
and in vitro. In the light of this fact, we assessed the 
effect of ginger extract on lymphocytes (as normal). Iso-
lated lymphocytes treated with ginger extract at varying 
doses of 0.001 - 1 mg/ml for 24 h (Figure 3) showed no 
significant effect on cell viability. This re-affirms the 
cancer preventive properties of ginger and the fact that it 
has relatively less (or no) toxicity to normal cells. Our 
study thus, provides corroborative evidence that Z. offici-
nale extract was selectively toxic against cancer cells.  
Our results are consistent with previous studies, 
wherein (6) -gingerol and ginger extract showed a dose 
dependent inhibition on the proliferation of HepG2 cell 
with a corresponding induction of apoptosis (Hanif et al., 
2007). The percentage of apoptotic cells were also 
reported to have increased in a dose- dependent manner 
(Yoo et al., 2002; Hanif et al., 2007). Ginger con-tains 
pungent ingredients including gingerol, shoagol and 
zingerone that have been found to possess 
pharmacological and physiological activities (Surh et al., 
1998). Ginger root and its main poly-phenolic consti-
tuents (gingerols and zerumbone) has been shown to ex-
hibit anti-inflammatory and anti-neoplastic activity (Yang 
et al., 2001; Chang et al., 2003; Kim et al., 2005; Kundu 
et al., 2009) in several cell types through inhibition of the 
transcription factor NF-B, involved in cell proliferation, 
sustained angiogenesis and evasion of apoptosis. [6]-
gingerol, is capable of killing cancer cells expressing 
mutant p53, overcoming the phenotypic resistance to 
chemotherapy- and irradiation-induced cell death (Yon et 
al., 2006).  
Common cancer therapies combined with these dietary  
compounds may exert enhanced antitumor activity 
through synergic action or compensation of inverse pro-
perties. The combination treatment may also decrease 
the systemic toxicity caused by chemotherapies or radio-
therapies because lower doses could be used, resulting 
in better survival (Surh, 2003; Dragnev et al., 2004). Our 
study, performed for the first time evaluated the efficacy 
of gemcitabine drug in par with a common dietary com-
ponent, ginger. The combinational effects of Z. officinale 
extract with gemcitabine on cell growth inhibition of the 
HeLa cells are shown in Figure 6. Our results demon-
strated a 39% cell death with 5 mM gemcitabine alone. 
Cells treated with 0.80 and 0.85 mg/ml of ginger extract 
individually showed a 6 and 30% decrease in cell viability 
respectively. Results of combination using ginger (at 
concentrations of 0.8 and 0.85 mg/ml) and gemcitabine 
(5 mM) demonstrates an even higher cell death ranging 
from (49-72% respectively). This affirms our hypothesis 
that combinational therapy could indeed improve drug 
efficacy even at lower doses of chemotherapeutic drugs 
and thereby minimize toxicity on normal cells. Thus, sub-
lethal doses of gemcitabine in combination with ginger 
extract increased effectiveness of the chemotherapeutic 
drug. Similar experiment was also performed with normal 
cells (data not shown). There was no significant decrease 
in cell viability on treatment of lymphocytes with combi-
nation of sub-lethal dose of gemcitabine (5 mM) and 
ginger extract (0.8 - 0.85 mg/ml).  
Earlier researches carried out on a chemopreventive 
agent, genistein in vitro, reported potentiation of growth 
inhibition and apoptotic cell death caused by chemo-
therapeutic drugs  cisplatin,  docetaxel,  doxorubicin  and  






Figure 6. The combination effect of gemcitabine (5 mM) and ginger extract (080 and 0.85 mg/ml) on 




gemcitabine in prostate, breast, pancreas and lung 
cancers (Banerjee et al., 2005; Li et al., 2005). Finding 
from previous studies also report that pretreatment of 
cancer cells with 15 to 30 mol/l genistein before the 
treatment with lower doses of chemotherapeutic agents 
had caused a significantly greater degree of growth inhi-
bition and apoptotic cell death, suggesting that increased 
antitumor activities of chemotherapeutic agents with 
lower toxicity to normal cells could be achieved by intro-
ducing genistein into the chemotherapeutic strategy. 
When the study was extended to in vivo model, it was 
observed that genistein could potentiate the antitumor 
activities of gemcitabine and docetaxel in a tumor model, 
resulting in more tumor cell killing and apoptotic cell 
death. Experimental results from earlier studies have 
suggested that a dietary agent could be used to enhance 
antitumor activities of chemotherapeutic agents both in 
vitro and in vivo in multiple tumors (Banerjee et al., 2005; 
Li et al., 2005). 
The results of this study indicate that ginger may exhibit 
its anti-neoplastic effects in cervical cancer. Also ginger 
can be used in combination with chemotherapeutic drugs 
to increase their efficacy and reducing their side effects. 
Further mechanistic studies as well as in vivo studies and 
clinical trials of chemopreventive action of ginger need to 
be performed to provide a platform for the development 
of ginger for therapeutic purposes.  
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